The recently developed DON prodrugs were designed to circulate in the plasma in an intact and inert form; the prodrugs are preferentially cleaved by tumor-enriched esterases and peptidases and release DON in the tumor microenvironment while remaining inactivated in non-tumor tissues to reduce damage to non-target tissues [18, 19]. The gene discussed is LAP3; the disease is neoplasm.